N/A
N=127
Deep Brain Stimulation (DBS) for the Suppression of Tremor
Tremor · Action Tremor · Essential Tremor · Tremor, Limb
Bottom Line
View on ClinicalTrials.gov: NCT02087046 ↗Enrolled (actual)
127
Serious AEs
22.1%
Results posted
Feb 2021
Primary outcome: Primary: Primary Efficacy Endpoint: Difference in the Postural Tremor Score of the Target Limb Between Stimulation On and Stimulation Off, As Assessed by the Blind Reviewer — 2.09; 0.84; -1.25 units on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- ANS Totally Implantable Deep Brain Stimulation System (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Abbott Medical Devices
- Primary completion
- Apr 2014
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Primary Efficacy Endpoint: Difference in the Postural Tremor Score of the Target Limb Between Stimulation On and Stimulation Off, As Assessed by the Blind Reviewer |
2.09; 0.84; -1.25 | — |
| PRIMARY Primary Safety Endpoint: Percentage of Participants With Device-related or Procedure Related Adverse Events |
31.5 | — |
| SECONDARY Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Target Limb Severity Score, As Assessed by the Site Physician |
2.55; 0.62; -1.94 | — |
| SECONDARY Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Target Limb Severity Score, As Assessed by the Site Physician |
2.55; 0.62; -1.94 | — |
| SECONDARY Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Target Limb Severity Score, As Assessed by the Site Physician |
2.55; 0.62; -1.94 | — |
| SECONDARY Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Target Limb Severity Score, As Assessed by the Site Physician |
2.55; 0.62; -1.94 | — |
| SECONDARY Clinical Rating Scale for Tremor (CRST) Evaluation- Target Limb Responder Analysis, As Assessed by the Site Physician |
72; 97 | — |
| SECONDARY Clinical Rating Scale for Tremor (CRST) Evaluation- Target Limb Responder Analysis, As Assessed by the Site Physician |
72; 97 | — |
| SECONDARY Clinical Rating Scale for Tremor (CRST) Evaluation- Target Limb Responder Analysis, As Assessed by the Site Physician |
72; 97 | — |
| SECONDARY Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Handwriting for Target Side Severity Score, As Assessed by the Site Physician |
2.32; 0.90; -1.42 | — |
| SECONDARY Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Handwriting for Target Side Severity Score, As Assessed by the Site Physician |
2.32; 0.90; -1.42 | — |
| SECONDARY Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Handwriting for Target Side Severity Score, As Assessed by the Site Physician |
2.32; 0.90; -1.42 | — |
| SECONDARY Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Handwriting for Target Side Severity Score, As Assessed by the Site Physician |
2.32; 0.90; -1.42 | — |
| SECONDARY Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Handwriting for Target Side Severity Score, As Assessed by the Blind Reviewer |
1.69; 0.62; -1.07 | — |
| SECONDARY Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Pouring From Target Side Severity Scores, As Assessed by the Site Physician |
2.08; 0.57; -1.52 | — |
| SECONDARY Clinical Rating Scale for Tremor (CRST) Evaluation-Mean Pouring From Target Side Severity Scores, As Assessed by the Site Physician |
2.16; 0.62; -1.54 | — |
| SECONDARY Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Pouring From Target Side Severity Scores, As Assessed by the Site Physician |
2.08; 0.57; -1.52 | — |
| SECONDARY Clinical Rating Scale for Tremor (CRST) Evaluation-Mean Pouring From Target Side Severity Scores, As Assessed by the Site Physician |
2.16; 0.62; -1.54 | — |
| SECONDARY Clinical Rating Scale for Tremor (CRST) Evaluation- Pouring Ability From Target Side Severity Scores, As Assessed by the Blind Reviewer |
1.56; 0.70; -0.86 | — |
| SECONDARY Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Total Motor Score, As Assessed by the Site Physician |
14.6; 7.2; -7.4 | — |
| SECONDARY Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Total Motor Score, As Assessed by the Site Physician |
14.6; 7.2; -7.4 | — |
| SECONDARY Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Total Motor Score, As Assessed by the Site Physician |
14.6; 7.2; -7.4 | — |
| SECONDARY Clinical Rating Scale for Tremor (CRST) Evaluation- Mean Total Motor Score, As Assessed by the Site Physician |
14.6; 7.2; -7.4 | — |
| SECONDARY Clinical Rating Scale for Tremor (CRST) Evaluation- Activity of Daily Living Score, As Assessed by the Site Physician |
14.7; 4.6; -10.0 | — |
| SECONDARY Clinical Rating Scale for Tremor (CRST) Evaluation- Activity of Daily Living Score, As Assessed by the Site Physician |
14.7; 4.6; -10.0 | — |
| SECONDARY Clinical Rating Scale for Tremor (CRST) Evaluation- Activity of Daily Living Score, As Assessed by the Site Physician |
14.7; 4.6; -10.0 | — |
| SECONDARY Clinical Rating Scale for Tremor (CRST) Evaluation- Activity of Daily Living Score, As Assessed by the Site Physician |
14.7; 4.6; -10.0 | — |
| SECONDARY Clinical Rating Scale for Tremor (CRST) Evaluation-Bilateral Stimulation, As Assessed by the Site Physician |
2.67; 0.95; -1.72 | — |
| SECONDARY Clinical Rating Scale for Tremor (CRST) Evaluation-Bilateral Stimulation, As Assessed by the Site Physician |
2.67; 0.95; -1.72 | — |
| SECONDARY Clinical Rating Scale for Tremor (CRST) Evaluation-Non-Target Limb Severity Scores, As Assessed by the Site Physician |
2.73; 1.11; -1.62 | — |
| SECONDARY Clinical Rating Scale for Tremor (CRST) Evaluation-Non-Target Limb Severity Scores, As Assessed by the Site Physician |
2.73; 1.11; -1.62 | — |
| SECONDARY Quality of Life in Essential Tremor (QUEST): Overall Summary Index |
49.1 | — |
| SECONDARY Change From Baseline for Quality of Life in Essential Tremor (QUEST): Overall Summary Index |
30.9; -18.0 | — |
| SECONDARY Change From Baseline for Quality of Life in Essential Tremor (QUEST): Overall Summary Index |
30.9; -18.0 | — |
| SECONDARY Change From Baseline for Quality of Life in Essential Tremor (QUEST): Overall Summary Index |
30.9; -18.0 | — |
| SECONDARY SF36 Components and Individual Domains |
45.6; 52.21 | — |
| SECONDARY SF36 Components and Individual Domains |
45.6; 52.21 | — |
| SECONDARY SF36 Components and Individual Domains |
45.6; 52.21 | — |
| SECONDARY SF36 Components and Individual Domains |
45.6; 52.21 | — |
| SECONDARY Global Assessment Scores by Examiner |
36; 55; 14; 4; 1 | — |
| SECONDARY Global Assessment Scores by Examiner |
36; 55; 14; 4; 1 | — |
| SECONDARY Global Assessment Scores by Examiner |
36; 55; 14; 4; 1 | — |
| SECONDARY Global Assessment Scores by Examiner |
36; 55; 14; 4; 1 | — |
| SECONDARY Global Assessment by Caregiver |
25; 28; 11; 4; 2 | — |
| SECONDARY Global Assessment by Caregiver |
25; 28; 11; 4; 2 | — |
| SECONDARY Global Assessment by Caregiver |
25; 28; 11; 4; 2 | — |
| SECONDARY Global Assessment by Caregiver |
25; 28; 11; 4; 2 | — |
| SECONDARY Global Assessment by Patient |
38; 45; 20; 6; 1 | — |
| SECONDARY Global Assessment by Patient |
38; 45; 20; 6; 1 | — |
| SECONDARY Global Assessment by Patient |
38; 45; 20; 6; 1 | — |
| SECONDARY Global Assessment by Patient |
38; 45; 20; 6; 1 | — |
| SECONDARY Subjective Assessment by Patient Since Activation of System |
17; 13; 16; 45; 14; 3 | — |
| SECONDARY Subjective Assessment by Patient Since Activation of System |
17; 13; 16; 45; 14; 3 | — |
| SECONDARY Subjective Assessment by Patient Since Activation of System |
17; 13; 16; 45; 14; 3 | — |
| SECONDARY Number of Participants With Satisfaction With the DBS System's Functioning and Ability to Control Symptoms |
76; 22; 2; 7; 3 | — |
| SECONDARY Number of Participants With Satisfaction With the DBS System's Functioning and Ability to Control Symptoms |
76; 22; 2; 7; 3 | — |
| SECONDARY Number of Participants With Satisfaction With the DBS System's Functioning and Ability to Control Symptoms |
76; 22; 2; 7; 3 | — |
| SECONDARY Number of Participants Who Would Choose to Receive the DBS System Again |
98 | — |
| SECONDARY Number of Participants Who Would Choose to Receive the DBS System Again |
98 | — |
| SECONDARY Number of Participants Who Would Choose to Receive the DBS System Again |
98 | — |
| SECONDARY Number of Participants Who Would Recommend the DBS System |
98 | — |
| SECONDARY Number of Participants Who Would Recommend the DBS System |
98 | — |
| SECONDARY Number of Participants Who Would Recommend the DBS System |
98 | — |
| SECONDARY Beck Depression Inventory II (BDI - II) Score for Depression Symptoms |
8.8 | — |
| SECONDARY Change From Baseline in Beck Depression Inventory II (BDI - II) Score for Depression Symptoms |
6.8; -2.0 | — |
| SECONDARY Mini Mental State Exam (MMSE) for Examination of Mental Status |
29.2 | — |
| SECONDARY Change From Baseline in Mini Mental State Exam (MMSE) For Examination of Mental Status |
29.1; -0.1 | — |
Summary
The purpose of the proposed study is to demonstrate the safety and efficacy of the ANS Totally Implantable Deep Brain Stimulation System in the VIM nucleus of the thalamus implanted for the treatment of tremor due to essential tremor.
This study will be included in the Pre-Market Approval Application to support the safety of this device in use.
Eligibility Criteria
Inclusion criteria
- Patient or authorized representative has signed an informed consent.
- Patient is over 18 years of age.
- Patient is diagnosed with essential tremor for at least 3 years.
- Patient has a disabling medical-refractory upper extremity tremor with no evidence of supraspinal central nervous system disease or injury (tremor not adequately controlled by medications for at least three (3) months before implant).
- Patient has a postural or kinetic tremor severity score of at least 3 out of 4 in the extremity intended for treatment on the Fahn-Tolosa-Marin Clinical Rating Scale for Tremor.
- Patient will maintain a constant dose of anti-tremor medication indicated as best medical management for one (1) month prior to enrollment in study.
- Patient is available for appropriate follow-up times for the length of the study.
Exclusion criteria
- Patient is not surgical candidate;
- Patient has other clinically or medically significant disease;
- Patient has any neurological injury or disease other than essential tremor;
- Patient has any condition requiring repeated MRI scans;
- Patient has any condition requiring diathermy;
- Patients on anticoagulant medications;
- Patient has untreated clinically significant depression;
- Patient has had an electrical or electromagnetic implant (cochlear prosthesis, pacemaker etc);
- Patient has had a prior thalamotomy or surgical ablation procedure in either side of the brain;
- Patient has dementia interfering with their ability to co-operate or comply with study requirements or comprehend the informed consent (mini-mental exam score <24);
- Patient abuses drugs or alcohol;
- Patient has had botulinum toxin injections in the six (6) months prior to enrollment;
- Patient has a history of cranial surgery;
- Patient has a history of seizures;
- Patient has any metallic implants that may interfere with the functioning of the device (e.g. aneurysm clips);
- Patient has a history of stimulation intolerance in any area of the body;
- Patient is a female of child bearing potential with a positive urine pregnancy test or not using adequate contraception.
Data sourced from ClinicalTrials.gov (NCT02087046). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.